[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604722":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":46,"collaborators":50,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":20,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":20,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":77,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Jan Biziel University Hospital No 2 in Bydgoszcz","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with SCS - tonic stimulation","EXPERIMENTAL","We plan to include 30-50 patients with PSPS or CRPS undergoing SCS implantation. Blood will be collected before surgery and 2-3 weeks after; CSF during both procedures. Pain (VAS), disability (ODI), neurological status, muscle tone, and analgesic intake will be assessed. Temporary stimulation will last 2-3 weeks before IPG implantation or electrode removal. Samples will be processed and analyzed via ELISA in our Biochemistry Department using established protocols.",[13],"Diagnostic Test: Immunological Factors",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","Immunological Factors","Assessment of interleukins and other molecues in CSF and blood of patients with SCS.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Oskar Puk Mr, MD","CONTACT","+48 52 365 5205","oskar.puk@biziel.pl",[28],{"facility":29,"status":30,"city":31,"state":20,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Jan Bizel University Hospital","RECRUITING","Bydgoszcz","85-168","Poland","PL",{"type":36,"coordinates":37},"Point",[38,39],18.00762,53.1235,{"lat":39,"lon":38},[42],{"name":43,"role":24,"phone":44,"phoneExt":20,"email":45},"Oskar Puk, MD","604875040","oskar.trebacz@gmail.com",{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"SPONSOR_INVESTIGATOR","Pawel Sokal","Professor",[51,54],{"name":52,"class":53},"Department of Neurosurgery Collegium Medicum Nicolaus Copernicus University","UNKNOWN",{"name":55,"class":6},"Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz","100604722","analysis-of-selected-biochemical-parameters-in-cerebrospinal-fluid-and-peripheral-blood-in-the-treatment-of-neuropathic-pain-using-spinal-cord-stimulation-scs-100604722",false,"NCT07153211","Analysis of Selected Biochemical Parameters in Cerebrospinal Fluid and Peripheral Blood in the Treatment of Neuropathic Pain Using Spinal Cord Stimulation (SCS)","Analysis of Selected Biochemical Parameters in Cerebrospinal Fluid and Peripheral Blood in the Treatment of Neuropathic Pain Using Spinal Cord Stimulation (SCS) Assessment of the Mechanism of Action of SCS and the Potential of Biochemical Studies in Therapy Planning and Monitoring","Inclusion Criteria:\n\n* Age 18-80\n* PSPS or CRPS\n* Neuropathic pain for at least 6 months\n\nExclusion Criteria:\n\n* Drug\u002Falcohol addiction\n* Malignant tumour\n* Psychiatric disorders\n* Active infection\n* Pregnancy","ALL","18 Years","80 Years",{"count":67,"type":68},30,"ESTIMATED","INTERVENTIONAL",[71],"NA","This project aims to identify key cells and molecules involved in the development and modulation of neuropathic pain treated with spinal cord stimulation (SCS). By measuring concentrations of selected inflammatory mediators and signaling molecules (e.g., IL-1β, IL-6, IL-17, IL-33, BDNF, VEGF, GABA) in the blood and cerebrospinal fluid (CSF) of patients undergoing SCS, the study seeks to better understand the mechanism of action of SCS. The findings may allow the development of predictive biomarkers, help tailor stimulation parameters, and support complementary pharmacotherapy. The project also explores differences in response to various stimulation types and the role of glial cells in SCS efficacy, with a view to improving patient outcomes through more personalized neuromodulation strategies.",[74,75,76],"Neuropathic Pain","Chronic Pain","Spinal Cord Stimulation (SCS)",[78,79,80],"spinal cord stimulation","neuropathic pain","immunomodulatory effects of scs","2025-08-29",{"date":83,"type":84},"2025-09-03","ACTUAL",{"date":86,"type":84},"2022-11-01",{"date":88,"type":68},"2026-12-31",{"name":48,"class":6},1]